

Calcium activated chloride channel (CaCC) in GtoPdb v.2025.3

Henry Danahay¹, Martin Gosling¹ and Paolo Tammaro²

1. Enterprise Therapeutics, UK
2. University of Oxford, UK

Abstract

Chloride channels activated by intracellular Ca^{2+} (CaCC) are widely expressed in excitable and non-excitabile cells where they perform diverse functions [25]. CaCCs are activated by a rise in intracellular free Ca^{2+} concentration ($[\text{Ca}^{2+}]_i$), typically following activation of G_q protein coupled receptors (G_qPCR). This section centres on CaCC channels encoded by the TMEM16A gene (HUGO gene nomenclature: Anoctamin 1). The TMEM16 family consists of 10 paralogs (TMEM16A-K; Anoctamin 1-10). The TMEM16A and TMEM16B genes (*ANO1* and *ANO2*) encode for CaCCs, while the other members function as lipid scramblases or have combined scramblase and non-selective ion channel function [26, 46, 18, 1, 41]. TMEM16A has a broad tissue distribution and a variety of established cellular roles, while the main physiological role for TMEM16B identified thus far is in olfaction [31, 16]. Alternative splicing regulates the voltage- and Ca^{2+} -dependence of TMEM16A and such post-transcriptional process may be tissue-specific and contribute to functional diversity [19]. TMEM16A is a potential drug target for a variety of conditions spanning from respiratory to vascular (see "Comments" section for further detail).

Contents

This is a citation summary for Calcium activated chloride channel (CaCC) in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [7].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

[Calcium activated chloride channel \(CaCC\)](#)

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=130>

Channels and Subunits

[CaCC](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708>

References

1. Agostinelli E and Tammaro P. (2022) Polymodal Control of TMEM16x Channels and Scramblases. *Int J Mol Sci* **23** [PMID:35163502]
2. Al-Hosni R, Agostinelli E, Ilkan Z, Scofano L, Kay R, Dinsdale RL, Acheson K, MacDonald A,

- Rivers D and Bioss A *et al.*. (2025) Pharmacological profiling of small molecule modulators of the TMEM16A channel and their implications for the control of artery and capillary function *BJP*
3. Al-Hosni R, Agostinelli E, Ilkan Z, Scofano L, Kaye R, Dinsdale RL, Acheson K, MacDonald A, Rivers D and Bioss A *et al.*. (2025) Pharmacological profiling of small molecule modulators of the TMEM16A channel and their implications for the control of artery and capillary function. *Br J Pharmacol* **182**: 1719-1740 [PMID:39829151]
4. Al-Hosni R, Ilkan Z, Agostinelli E and Tammaro P. (2022) The pharmacology of the TMEM16A channel: therapeutic opportunities. *Trends Pharmacol Sci* **43**: 712-725 [PMID:35811176]
5. Bai X, Cheng Y, Wan H, Li S, Kang X and Guo S. (2023) Natural Compound Allicin Containing Thiosulfinate Moieties as Transmembrane Protein 16A (TMEM16A) Ion Channel Inhibitor for Food Adjuvant Therapy of Lung Cancer. *J Agric Food Chem* **71**: 535-545 [PMID:36574498]
6. Boedtker DM, Kim S, Jensen AB, Matchkov VM and Andersson KE. (2015) New selective inhibitors of calcium-activated chloride channels - T16A(inh) -A01, CaCC(inh) -A01 and MONNA - what do they inhibit? *Br J Pharmacol* **172**: 4158-72 [PMID:26013995]
7. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
8. Cherian OL, Menini A and Boccaccio A. (2015) Multiple effects of anthracene-9-carboxylic acid on the TMEM16B/anoctamin2 calcium-activated chloride channel. *Biochim Biophys Acta* **1848**: 1005-13 [PMID:25620774]
9. Cil O, Anderson MO, Yen R, Kelleher B, Huynh TL, Seo Y, Nilsen SP, Turner JR and Verkman AS. (2019) Slowed gastric emptying and improved oral glucose tolerance produced by a nanomolar-potency inhibitor of calcium-activated chloride channel TMEM16A. *FASEB J* **33**: 11247-11257 [PMID:31299174]
10. Cil O, Chen X, Askew Page HR, Baldwin SN, Jordan MC, Myat Thwe P, Anderson MO, Haggie PM, Greenwood IA and Roos KP *et al.*. (2021) A small molecule inhibitor of the chloride channel TMEM16A blocks vascular smooth muscle contraction and lowers blood pressure in spontaneously hypertensive rats. *Kidney Int* **100**: 311-320 [PMID:33836171]
11. Danahay H, Fox R, Lilley S, Charlton H, Adley K, Christie L, Ansari E, Ehre C, Flen A and Tuvim MJ *et al.*. (2020) Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction. *FASEB Bioadv* **2**: 464-477 [PMID:32821878]
12. Danahay H and Gosling M. (2020) TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis? *Int J Mol Sci* **21** [PMID:32235608]
13. Danahay H, Lilley S, Adley K, Charlton H, Fox R and Gosling M. (2023) Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A. *Front Pharmacol* **14**: 1142342 [PMID:36950016]
14. Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, McCarthy C, Collingwood SP and Gosling M. (2020) TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis. *Am J Respir Crit Care Med* **201**: 946-954 [PMID:31898911]
15. De La Fuente R, Namkung W, Mills A and Verkman AS. (2008) Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel. *Mol Pharmacol* **73**: 758-68 [PMID:18083779]
16. Dibattista M, Pifferi S, Hernandez-Clavijo A and Menini A. (2024) The physiological roles of anoctamin2/TMEM16B and anoctamin1/TMEM16A in chemical senses. *Cell Calcium* **120**: 102889 [PMID:38677213]
17. Fedigan S, Bradley E, Webb T, Large RJ, Hollywood MA, Thornbury KD, McHale NG and Sergeant GP. (2017) Effects of new-generation TMEM16A inhibitors on calcium-activated chloride currents in rabbit urethral interstitial cells of Cajal. *Pflugers Arch* **469**: 1443-1455 [PMID:28733893]
18. Feng Z, Di Zanni E, Alvarenga O, Chakraborty S, Rychlik N and Accardi A. (2024) In or out of the groove? Mechanisms of lipid scrambling by TMEM16 proteins. *Cell Calcium* **121**: 102896 [PMID:38749289]
19. Ferrera L, Caputo A, Ubbi I, Bussani E, Zegarra-Moran O, Ravazzolo R, Pagani F and Galiotta LJ. (2009) Regulation of TMEM16A chloride channel properties by alternative splicing. *J Biol Chem* **284**: 33360-8 [PMID:19819874]
20. Galiotta LJ. (2022) TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. *Curr Opin Pharmacol* **64**: 102206 [PMID:35364521]
21. Genovese M, Borrelli A, Venturini A, Guidone D, Caci E, Viscido G, Gambardella G, di Bernardo D, Scudieri P and Galiotta LJ. (2019) TRPV4 and purinergic receptor signalling pathways are separately linked in airway epithelia to CFTR and TMEM16A chloride channels. *J Physiol* **597**: 5859-5878 [PMID:31622498]
22. Genovese M, Buccrossi M, Guidone D, De Cegli R, Sarnataro S, di Bernardo D and Galiotta LJ. (2023) Analysis of inhibitors of the anoctamin-1 chloride channel (transmembrane member 16A, TMEM16A) reveals indirect mechanisms involving alterations in calcium signalling. *Br J Pharmacol* **180**: 775-785 [PMID:36444690]

23. Genovese M and Galletta LJV. (2024) Anoctamin pharmacology. *Cell Calcium* **121**: 102905 [PMID:38788257]
24. Greenwood IA and Leblanc N. (2007) Overlapping pharmacology of Ca²⁺-activated Cl⁻ and K⁺ channels. *Trends Pharmacol Sci* **28**: 1-5 [PMID:17150263]
25. Hartzell C, Putzier I and Arreola J. (2005) Calcium-activated chloride channels. *Annu Rev Physiol* **67**: 719-58 [PMID:15709976]
26. Hawn MB, Akin E, Hartzell HC, Greenwood IA and Leblanc N. (2021) Molecular mechanisms of activation and regulation of ANO1-Encoded Ca²⁺-Activated Cl⁻ channels. *Channels (Austin)* **15**: 569-603 [PMID:34488544]
27. Ho MW, Shears SB, Bruzik KS, Duszyk M and French AS. (1997) Ins(3,4,5,6)P₄ specifically inhibits a receptor-mediated Ca²⁺-dependent Cl⁻ current in CFPAC-1 cells. *Am J Physiol* **272**: C1160-8 [PMID:9142840]
28. Hu Y, Zhang Y, He J, Rao H, Zhang D, Shen Z and Zhou C. (2025) ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases. *Front Immunol* **16**: 1570333 [PMID:40356890]
29. Huang F, Wong X and Jan LY. (2012) International Union of Basic and Clinical Pharmacology. LXXXV: calcium-activated chloride channels. *Pharmacol Rev* **64**: 1-15 [PMID:22090471]
30. Kaye R, Pearson C, Babiker T, Agostinelli E, Al-Hosni R and Tammam P. (2025) Clinically relevant niclosamide concentrations modulate TMEM16A and Ca_v1.2 channels to control artery tone and capillary diameter. *Br J Pharmacol* [PMID:40491382]
31. Leblanc N, Forrest AS, Ayon RJ, Wiwchar M, Angermann JE, Pritchard HA, Singer CA, Valencik ML, Britton F and Greenwood IA. (2015) Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle. *Pulm Circ* **5**: 244-68 [PMID:26064450]
32. Leblanc N, Ledoux J, Saleh S, Sanguinetti A, Angermann J, O'Driscoll K, Britton F, Perrino BA and Greenwood IA. (2005) Regulation of calcium-activated chloride channels in smooth muscle cells: a complex picture is emerging. *Can J Physiol Pharmacol* **83**: 541-56 [PMID:16091780]
33. Li S, Sun W, Li S, Zhu L, Guo S, He J, Li Y, Tian C, Zhao Z and Yu T *et al.*. (2025) Tamsulosin ameliorates bone loss by inhibiting the release of Cl⁻ through wedging into an allosteric site of TMEM16A. *Proc Natl Acad Sci U S A* **122**: e2407493121 [PMID:39739807]
34. Liang P, Wan YCS, Yu K, Hartzell HC and Yang H. (2024) Niclosamide potentiates TMEM16A and induces vasoconstriction. *J Gen Physiol* **156** [PMID:38814250]
35. Liu B, Linley JE, Du X, Zhang X, Ooi L, Zhang H and Gamper N. (2010) The acute nociceptive signals induced by bradykinin in rat sensory neurons are mediated by inhibition of M-type K⁺ channels and activation of Ca²⁺-activated Cl⁻ channels. *J Clin Invest* **120**: 1240-52 [PMID:20335661]
36. Liu S, Feng J, Luo J, Yang P, Brett TJ and Hu H. (2016) Eact, a small molecule activator of TMEM16A, activates TRPV1 and elicits pain- and itch-related behaviours. *Br J Pharmacol* **173**: 1208-18 [PMID:26756551]
37. Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, Elliott R, Chen JJ, Liu L and Leith A *et al.*. (2019) Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways. *Front Pharmacol* **10**: 51 [PMID:30837866]
38. Namkung W, Thiagarajah JR, Phuan PW and Verkman AS. (2010) Inhibition of Ca²⁺-activated Cl⁻ channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea. *FASEB J* **24**: 4178-86 [PMID:20581223]
39. Oh SJ, Hwang SJ, Jung J, Yu K, Kim J, Choi JY, Hartzell HC, Roh EJ and Lee CJ. (2013) MONNA, a potent and selective blocker for transmembrane protein with unknown function 16/noctamin-1. *Mol Pharmacol* **84**: 726-35 [PMID:23997117]
40. Piechowicz KA, Truong EC, Javed KM, Chaney RR, Wu JY, Phuan PW, Verkman AS and Anderson MO. (2016) Synthesis and evaluation of 5,6-disubstituted thiopyrimidine aryl aminothiazoles as inhibitors of the calcium-activated chloride channel TMEM16A/Ano1. *J Enzyme Inhib Med Chem* **31**: 1362-8 [PMID:26796863]
41. Pifferi S, Dibattista M and Menini A. (2009) TMEM16B induces chloride currents activated by calcium in mammalian cells. *Pflugers Arch* **458**: 1023-38 [PMID:19475416]
42. Pinto MC, Silva IAL, Figueira MF, Amaral MD and Lopes-Pacheco M. (2021) Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. *J Exp Pharmacol* **13**: 693-723 [PMID:34326672]
43. Piper AS, Greenwood IA and Large WA. (2002) Dual effect of blocking agents on Ca²⁺-activated Cl(-) currents in rabbit pulmonary artery smooth muscle cells. *J Physiol* **539**: 119-31 [PMID:11850506]
44. Qu Z, Yao W, Yao R, Liu X, Yu K and Hartzell C. (2014) The Ca(2+) -activated Cl(-) channel, ANO1 (TMEM16A), is a double-edged sword in cell proliferation and tumorigenesis. *Cancer Med* **3**: 453-61 [PMID:24639373]
45. Sabirova RKh and Farkhutdinov RG. (1972) [Changes in serotonin metabolism in patients with

- hypertension]. *Kardiologia* **12**: 19-22 [PMID:4642630]
46. Schreiber R, Ousingawat J and Kunzelmann K. (2024) The anoctamins: Structure and function. *Cell Calcium* **120**: 102885 [PMID:38642428]
47. Seo Y, Lee HK, Park J, Jeon DK, Jo S, Jo M and Namkung W. (2016) Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2. *PLoS One* **11**: e0155771 [PMID:27219012]
48. Shi S, Ma B, Sun F, Qu C and An H. (2021) Theaflavin binds to a druggable pocket of TMEM16A channel and inhibits lung adenocarcinoma cell viability. *J Biol Chem* **297**: 101016 [PMID:34329684]
49. Ta CM, Adomaviciene A, Rorsman NJ, Garnett H and Tammaro P. (2016) Mechanism of allosteric activation of TMEM16A/ANO1 channels by a commonly used chloride channel blocker. *Br J Pharmacol* **173**: 511-28 [PMID:26562072]
50. Tradtrantip L, Namkung W and Verkman AS. (2010) Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from *Croton lechleri*, targets two distinct intestinal chloride channels. *Mol Pharmacol* **77**: 69-78 [PMID:19808995]
51. Truong EC, Phuan PW, Reggi AL, Ferrera L, Galletta LJV, Levy SE, Moises AC, Cil O, Diez-Cecilia E and Lee S *et al.*. (2017) Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). *J Med Chem* **60**: 4626-4635 [PMID:28493701]
52. Verkman AS and Namkung W. (2017) Small molecule activators of calcium-activated chloride channels and methods of use Patent number: US9790218B2. Assignee: University of California. Priority date: 03/08/2012. Publication date: 17/10/2017.
53. Wray S, Prendergast C and Arrowsmith S. (2021) Calcium-Activated Chloride Channels in Myometrial and Vascular Smooth Muscle. *Front Physiol* **12**: 751008 [PMID:34867456]
54. Zhao Z, Xue Y, Zhang G, Jia J, Xiu R, Jia Y, Wang Y, Wang X, Li H and Chen P *et al.*. (2021) Identification of evodiamine and rutecarpine as novel TMEM16A inhibitors and their inhibitory effects on peristalsis in isolated Guinea-pig ileum. *Eur J Pharmacol* **908**: 174340 [PMID:34265294]